These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunotoxins in the treatment of hematologic malignancies. Kreitman RJ; Pastan I Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592 [TBL] [Abstract][Full Text] [Related]
3. Anthrax fusion protein therapy of cancer. Frankel AE; Powell BL; Duesbery NS; Vande Woude GF; Leppla SH Curr Protein Pept Sci; 2002 Aug; 3(4):399-407. PubMed ID: 12370003 [TBL] [Abstract][Full Text] [Related]
6. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Kreitman RJ Curr Pharm Des; 2009; 15(23):2652-64. PubMed ID: 19689336 [TBL] [Abstract][Full Text] [Related]
7. Recombinant immunotoxins for the treatment of haematological malignancies. Kreitman RJ Expert Opin Biol Ther; 2004 Jul; 4(7):1115-28. PubMed ID: 15268678 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of anticancer immunotoxins. Choudhary S; Mathew M; Verma RS Drug Discov Today; 2011 Jun; 16(11-12):495-503. PubMed ID: 21511052 [TBL] [Abstract][Full Text] [Related]
9. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Keppler-Hafkemeyer A; Kreitman RJ; Pastan I Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457 [TBL] [Abstract][Full Text] [Related]
10. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Frankel AE; Sievers EL; Scheinberg DA Cancer Biother Radiopharm; 2000 Oct; 15(5):459-76. PubMed ID: 11155818 [TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
13. Immunotoxins and cancer therapy. Li Z; Yu T; Zhao P; Ma J Cell Mol Immunol; 2005 Apr; 2(2):106-12. PubMed ID: 16191416 [TBL] [Abstract][Full Text] [Related]
14. Immunotoxin therapy for hematologic malignancies: where are we heading? Madhumathi J; Devilakshmi S; Sridevi S; Verma RS Drug Discov Today; 2016 Feb; 21(2):325-32. PubMed ID: 26049016 [TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma. Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960 [TBL] [Abstract][Full Text] [Related]
17. Immunotoxins: a clinical review of their use in the treatment of malignancies. Hertler AA; Frankel AE J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183 [TBL] [Abstract][Full Text] [Related]
18. Immunotoxins in cancer therapy: Review and update. Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218 [TBL] [Abstract][Full Text] [Related]